[June 18, 2015]

CorPath® System Robotically Deployed Bioresorbable Vascular Scaffold During Live Broadcast of a Complex Coronary Intervention at 2015 C3 Conference

Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that a complex percutaneous coronary intervention (PCI (News - Alert)) was broadcast live to attendees of the 2015 Complex Cardiovascular Catheter Therapeutics Conference in Orlando, Florida. Interventional cardiologists from around the world watched Arif Al Nooryani, MD, perform the triple-vessel disease case robotically in real-time by deploying bioresorbable stents, wiring the lesion and placing the stents using the CorPath System.

During the procedure, Dr. Al Nooryani, Chief Executive Officer and Head of the Cardiology Department at Al Qassimi Hospital, Sharjah, United Arab Emirates, sat in the CorPath System's radiation-shielded interventional cockpit and did not need to wear a lead apron as he advanced the guidewires, balloons, and stents without being exposed to the hazards of x-ray radiation.

"This case showed how robotic technology is effective in the treatment of patients with complex disease, while protecting me from the occupational hazards of the cath lab," said Dr. Al Nooryani. "The enhanced visualization and precision provided by the CorPath System enabled me to place the bioresorbable vascular scaffold with optimal results for my patient."

Developed by Corindus Vascular Robotics, the CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to coronary interventional procedures. The CorPath System is currently indicated in the US only for percutaneous coronary interventions.

For more information about the CorPath System, visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company's FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement with manual PCI procedures. Corindus Vascular Robotics stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus Vascular Robotics to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus Vascular Robotics' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of Corindus Vascular Robotics. Examples of such statements include statements regarding the potential benefits of the CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of the CorPath System and the rate of use of CorPath Cassettes; risks associated with market acceptance, including pricing and reimbursement; Corindus Vascular Robotics' ability to enforce its intellectual property rights; the need for additional funds to support operations; the ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend sales; and the effect of credit, financial and economic conditions on capital spending by potential customers. More information on potential factors that could affect Corindus Vascular Robotics' financial results is included from time to time in the "Forward-Looking Statements," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus Vascular Robotics' periodic and current filings with the SEC (News - Alert), as well as those discussed under the "Risk Factors" and "Forward-Looking Statements" section of Corindus Vascular Robotics' Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on its website at http://www.corindus.com/about-corindus/investor-relations. Forward-looking statements speak only as of the date they are made and Corindus Vascular Robotics undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, that occur after that date.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150618005648/en/

[ Back To TMCnet.com's Homepage ]